新研究旨在优化盘尾丝虫病的治疗。
New Research Aims to Optimize Therapy Against Onchocerciasis.
机构信息
John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Senior Lecturer, School of Public Health, University of Health and Allied Sciences, Ho, Ghana.
出版信息
Mo Med. 2022 Jan-Feb;119(1):55-59.
Abstract
Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.
摘要
盘尾丝虫病是一种寄生虫病，是世界上第二大致盲的传染病，影响 2500 万人，主要在撒哈拉以南非洲。用伊维菌素进行大规模药物治疗（MDA）一直是减少失明负担的成功国际努力的基础。尽管通过 MDA 用伊维菌素改善了感染率和失明情况，但这种药物并不能杀死或永久杀死成虫，它们可以存活超过 10 年。因此，寻找盘尾丝虫病的新疗法对于加速消除这种致盲疾病至关重要。在这里，我们讨论一项新的盘尾丝虫病治疗方法的研究进展。
相似文献
1
New Research Aims to Optimize Therapy Against Onchocerciasis.新研究旨在优化盘尾丝虫病的治疗。
Mo Med. 2022 Jan-Feb;119(1):55-59.
2
The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.因盘尾丝虫病而罹患皮肤病和眼病的负担，在曾由非洲盘尾丝虫病控制规划负责的国家，分别为 1990 年、2020 年和 2030 年。
PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009604. doi: 10.1371/journal.pntd.0009604. eCollection 2021 Jul.
3
Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.确定撒哈拉以南非洲地区主要丝虫病的共同流行地区：在大规模药物治疗运动中寻求协同作用并预防严重不良事件。
Parasit Vectors. 2018 Jan 31;11(1):70. doi: 10.1186/s13071-018-2655-5.
4
Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.哥伦比亚消除盘尾丝虫病：世界上首次证明消除河盲症的概念。
Parasit Vectors. 2018 Apr 11;11(1):237. doi: 10.1186/s13071-018-2821-9.
5
Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa.非洲盘尾丝虫病（河盲症）消除和根除工作的经济成本
PLoS Negl Trop Dis. 2015 Sep 11;9(9):e0004056. doi: 10.1371/journal.pntd.0004056. eCollection 2015.
6
Onchocerciasis and other eye problems in developing countries: a challenge for optometrists.发展中国家的盘尾丝虫病及其他眼部问题：验光师面临的一项挑战
J Am Optom Assoc. 1993 Oct;64(10):699-702.
7
Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective.到 2025 年在非洲消除盘尾丝虫病：需要有广阔的视角。
Infect Dis Poverty. 2019 Jul 15;8(1):50. doi: 10.1186/s40249-019-0557-1.
8
Contribution and performance of female Community-Directed Distributors in the treatment of onchocerciasis with Ivermectin in Sub-Saharan Africa: a systematic review.撒哈拉以南非洲地区女性社区导向分发员在伊维菌素治疗盘尾丝虫病中的贡献与表现：一项系统评价
Pan Afr Med J. 2015 Feb 27;20:188. doi: 10.11604/pamj.2015.20.188.3337. eCollection 2015.
9
Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin.在加纳选择的低度流行社区中，长期使用伊维菌素后盘尾丝虫病的流行情况及相关临床表现。
BMC Infect Dis. 2019 May 17;19(1):431. doi: 10.1186/s12879-019-4076-2.
10
Eliminating onchocerciasis as a public health problem: the beginning of the end.消除盘尾丝虫病这一公共卫生问题：终结的开端。
Br J Ophthalmol. 2002 Aug;86(8):844-6. doi: 10.1136/bjo.86.8.844.
引用本文的文献
1
Current perspectives in the epidemiology and control of lymphatic filariasis.淋巴丝虫病流行病学与防治的当前观点
Clin Microbiol Rev. 2025 Jun 12;38(2):e0012623. doi: 10.1128/cmr.00126-23. Epub 2025 Apr 2.
2
The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.控制和消除被忽视热带病的药物研发管道：2. 用于标签外使用的口服抗感染药物和药物组合。
Parasit Vectors. 2023 Oct 31;16(1):394. doi: 10.1186/s13071-023-05909-8.
本文引用的文献
1
The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.双、三药社区全民药物治疗丝虫病的安全性：一项多中心、开放性、整群随机研究。
PLoS Med. 2019 Jun 24;16(6):e1002839. doi: 10.1371/journal.pmed.1002839. eCollection 2019 Jun.
2
A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.一种治疗丝虫病的三药疗法试验。
N Engl J Med. 2018 Nov 8;379(19):1801-1810. doi: 10.1056/NEJMoa1706854.
3
The global burden of disease study 2013: What does it mean for the NTDs?《2013年全球疾病负担研究：对被忽视热带病意味着什么？》
PLoS Negl Trop Dis. 2017 Aug 3;11(8):e0005424. doi: 10.1371/journal.pntd.0005424. eCollection 2017 Aug.
4
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.伊维菌素、乙胺嗪和阿苯达唑三联疗法（IDA）对加速非洲消除淋巴丝虫病和盘尾丝虫病的潜在价值。
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163. doi: 10.1371/journal.pntd.0005163. eCollection 2017 Jan.
5
The First Confirmed Elimination of an Onchocerciasis Focus in Africa: Abu Hamed, Sudan.非洲首个盘尾丝虫病流行区得到确认消除：苏丹阿布哈迈德
Am J Trop Med Hyg. 2016 Nov 2;95(5):1037-1040. doi: 10.4269/ajtmh.16-0274. Epub 2016 Jun 27.
6
Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal.在非洲流行区使用伊维菌素治疗消灭盘尾丝虫病的原理验证：马里和塞内加尔研究的最终结果。
PLoS Negl Trop Dis. 2012;6(9):e1825. doi: 10.1371/journal.pntd.0001825. Epub 2012 Sep 13.
7
Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.在非洲流行区使用伊维菌素治疗消灭盘尾丝虫病的可行性：来自马里和塞内加尔研究的初步证据。
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497. doi: 10.1371/journal.pntd.0000497.
8
Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.单剂量伊维菌素对盘尾丝虫的影响：一项系统评价和荟萃分析。
Lancet Infect Dis. 2008 May;8(5):310-22. doi: 10.1016/S1473-3099(08)70099-9.
9
Ophthalmic imaging by spectral optical coherence tomography.通过光谱光学相干断层扫描进行眼科成像。
Am J Ophthalmol. 2004 Sep;138(3):412-9. doi: 10.1016/j.ajo.2004.04.049.
10
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.乙胺嗪治疗盘尾丝虫病的眼部和全身并发症：与循环免疫复合物的关联。
J Infect Dis. 1983 May;147(5):890-7. doi: 10.1093/infdis/147.5.890.
Zotero 插件